Bridgewater, N.J. – October 30, 2026 -- RVL Pharmaceuticals reported double-digit year-over-year revenue growth in the third quarter, driven by rising consumer demand for its prescription eye drop Upneeq, a national celebrity campaign and a widened product line.
Upneeq anchors RVL's vertically integrated platform
Upneeq (oxymetazoline hydrochloride ophthalmic solution, 0.1%) treats acquired blepharoptosis, or low-lying eyelids. It is the core asset of RVL's omnichannel platform, which combines consumer demand generation, healthcare provider engagement, telemedicine, pharmacy fulfillment and data-driven insights. RVL puts the total addressable market for Upneeq at an estimated $2.5 billion.
National celebrity campaign launched in Q2 gathered pace in Q3
RVL started its first national consumer celebrity campaign in the second quarter and kept expanding it through Q3. During the period, the company hosted a discussion with New York dermatologist Dr. Elizabeth Hale and Fat Mascara host Jessica Matlin for media. It also ran a New York Fashion Week activation the same day, with attendees ranging from eyecare professionals to influencers.
Chief Growth Officer Amy Shah said the campaign generated broad earned media coverage and educated millions of potential new customers about low-lying eyelids.
Upneeq Reveal Under Eye Complex extends the brand into skincare
RVL grew Upneeq Reveal Under Eye Complex, its first consumer product extension into skincare. The non-prescription cosmetic product contains no oxymetazoline and targets dark circles, fine lines and wrinkles. RVL says the extension broadens its addressable market and adds pathways for lifetime value growth across prescription and consumer channels.
CEO Lori Deo described the quarter as "an important step" in the company's shift from a prescription brand toward a broader presence in ocular aesthetics.
RVL plans further investment in awareness, innovation and commercial capabilities
Building on third-quarter momentum, RVL intends to keep investing in consumer awareness, innovation and commercial capabilities. The aim is to expand access to Upneeq and strengthen engagement across the customer journey. The company did not disclose absolute revenue figures.